Our seminal discovery of HMGB1 as a late mediator of lethal endotoxemia has stimulated extensive interest in search for HMGB1-targeting pharmacological inhibitors ranging from small molecules to large biological agents. The gene discussed is HMGB1; the disease is serum lipopolysaccharide activity.